Skip to main content
NIH funding notice RFA-MH-22-281

Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies (R21 Clinical Trial Not Allowed)

Closed on December 5, 2022.

Posted
July 11, 2022
Close date
December 5, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $672,250 in first-year total cost, median $336,125.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-G (03)]2

Most frequent institutions

  1. TEMPLE UNIV OF THE COMMONWEALTH1
  2. UNIVERSITY OF CALIFORNIA, SAN DIEGO1
Competing awards under RFA-MH-22-281 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Mechanisms controlling HIV latency and pathogenesis in microglia1R21MH134401-01SCHLACHETZKI, JOHANNES CAROLUS MAGNUSYANG, XIAOXUUNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$434,500ZMH1
2023Productive and latent HIV infection of microglia: virus and host wrestle for SUMOylation system control1R21MH134390-01LANGFORD, DIANNE TERESATEMPLE UNIV OF THE COMMONWEALTH, PA$237,750ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.